Minimal methylation classifier (MIMIC): A novel method for derivation and rapid diagnostic detection of disease-associated DNA methylation signatures

被引:0
作者
E. C. Schwalbe
D. Hicks
G. Rafiee
M. Bashton
H. Gohlke
A. Enshaei
S. Potluri
J. Matthiesen
M. Mather
P. Taleongpong
R. Chaston
A. Silmon
A. Curtis
J. C. Lindsey
S. Crosier
A. J. Smith
T. Goschzik
F. Doz
S. Rutkowski
B. Lannering
T. Pietsch
S. Bailey
D. Williamson
S. C. Clifford
机构
[1] Northern Institute for Cancer Research,Wolfson Childhood Cancer Research Centre
[2] Newcastle University,Department of Pediatrics
[3] Northumbria University,undefined
[4] Agena,undefined
[5] NewGene,undefined
[6] Department of Neuropathology,undefined
[7] University of Bonn Medical Center,undefined
[8] Institut Curie and University Paris Descartes,undefined
[9] University Medical Center Hamburg-Eppendorf,undefined
[10] University of Gothenburg and the Queen Silvia Children’s Hospital,undefined
[11] Queen’s University,undefined
[12] ,undefined
来源
Scientific Reports | / 7卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Rapid and reliable detection of disease-associated DNA methylation patterns has major potential to advance molecular diagnostics and underpin research investigations. We describe the development and validation of minimal methylation classifier (MIMIC), combining CpG signature design from genome-wide datasets, multiplex-PCR and detection by single-base extension and MALDI-TOF mass spectrometry, in a novel method to assess multi-locus DNA methylation profiles within routine clinically-applicable assays. We illustrate the application of MIMIC to successfully identify the methylation-dependent diagnostic molecular subgroups of medulloblastoma (the most common malignant childhood brain tumour), using scant/low-quality samples remaining from the most recently completed pan-European medulloblastoma clinical trial, refractory to analysis by conventional genome-wide DNA methylation analysis. Using this approach, we identify critical DNA methylation patterns from previously inaccessible cohorts, and reveal novel survival differences between the medulloblastoma disease subgroups with significant potential for clinical exploitation.
引用
收藏
相关论文
共 27 条
[11]  
Bibikova M(2000)Single-nucleotide polymorphism analysis by MALDI-TOF mass spectrometry Trends In Biotechnology 18 77-84
[12]  
Wang RY(2009)& Clifford, S.C. The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials British Journal Of Neurosurgery 23 364-375
[13]  
Gehrke CW(2013)DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies Acta Neuropathologica 125 359-371
[14]  
Ehrlich M(2013)Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays Acta Neuropathologica 125 913-916
[15]  
Griffin TJ(2012)Molecular subgroups of medulloblastoma: the current consensus Acta Neuropathologica 123 465-472
[16]  
Smith LM(2012)Hyperfractionated Versus Conventional Radiotherapy Followed by Chemotherapy in Standard-Risk Medulloblastoma: Results From the Randomized Multicenter HIT-SIOP PNET 4 Trial Journal of Clinical Oncology 30 3187-3193
[17]  
Pizer BL(2015)Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial Oncotarget 6 38827-38839
[18]  
Schwalbe EC(2004)Metagenes and molecular pattern discovery using matrix factorization Proceedings of the National Academy of Sciences of the United States of America 101 4164-4169
[19]  
Hovestadt V(2015)Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease Cancer Cell 27 72-84
[20]  
Taylor MD(undefined)undefined undefined undefined undefined-undefined